Experience with precision genomics and tumor board indicates frequent target identification but barriers to delivery

摘要

BackgroundThe ability to analyze the genomics of malignancies has opened up new possibilities for off-label targeted therapy in cancers that are refractory to standard therapy. At Mayo Clinic these efforts are organized through the Center for Individualized Medicine (CIM).